Free press releases distribution network?

Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New Gastrointestinal Tract Infections Assays Launch in Europe - BD and Diagenode Introduce Enteric Viral and Bacterial Panels on the BD MAX™ System - /
New Gastrointestinal Tract Infections Assays Launch in Europe


PRZOOM - /newswire/ - Baltimore, MD, United States, 2013/04/17 - BD and Diagenode Introduce Enteric Viral and Bacterial Panels on the BD MAX™ System - / NYSE: BDX

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company), and Diagenode SA, an international biotech company based in Belgium, announced today the availability of the CE-marked Diagenode Enteric Viral Panel primers and probes kit that is used with the BD MAX™ RNA extraction kit RNA3 and BD MAX™ PCR Cartridges. In addition, BD announced the availability of the CE-marked BD MAX™ Enteric Bacterial Panel for use on the BD MAX™ System.

The Diagenode Enteric Viral Panel primers and probes kit is an automated in vitro diagnostic (IVD) test for the qualitative detection of norovirus (genogroups I and II) and rotavirus species in stool specimens. The BD MAX Enteric Bacterial Panel is a qualitative IVD test detecting DNA from Campylobacter spp. (jejuni and coli), Salmonella spp., Shigellosis disease (Shigella spp./Enteroinvasive E. coli [EIEC]) as well as Shiga-toxin Types 1a and 2a in stool specimens.

“The expanding BD MAX System product menu and open system capabilities, full automation and standardized workflow will enable laboratories to consolidate and standardize a broad range of molecular tests to build programs that meet both their current and future clinical needs,” said Tom Polen, President, BD Diagnostics Diagnostic Systems. “BD’s suite of enteric assays on the BD MAX System will allow for targeted testing needs based on patient and clinical presentation, optimizing both clinical and economic outcomes.”

Infectious gastroenteritis accounts for 1 billion cases of diarrhea globally and more than 2 million deaths annually. These infections may be caused by viruses, bacteria or parasites and often take two to three days to identify in the clinical laboratory using conventional methods. Enteric viruses are the most common cause, accounting for millions of gastroenteritis cases annually across the European Union. During 2012 several countries across the European Union saw an increase of as much as 83 percent in the number of cases reported as compared to last year. Early and rapid diagnosis is critical in stopping the transmission of this highly contagious disease.[1]

These new products available on the BD MAX System provide laboratory technicians with a fully automated system that standardizes the extraction process and offers ease-of-use and improved laboratory workflow. “The Diagenode Enteric Viral Panel kit offers the capability to test for both norovirus and rotavirus as part of a fully validated, CE-marked product on the BD MAX System. This further leverages the unique open system capability of the instrument as well as our IVD development expertise to provide a diagnostic offering for the enteric disease syndrome,” stated Didier Allaer, CEO of Diagenode.

In addition to panels detecting enteric viral and bacterial pathogens, a BD MAX™ Enteric Ovum and Parasite Panel is currently in development for the qualitative detection of parasitic enteric pathogens Giardia lamblia, Cryptosporidium spp. (C. hominus andC. parvum), and Entamoeba histolytica directly from stool specimens in patients with signs and symptoms of gastroenteritis and/or colitis.

BD plans to continue expanding the BD MAX molecular testing menu through internal development and the Diagenode collaboration by launching additional assays throughout 2013.

About BD
BD ( is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

About Diagenode
Diagenode ( is a leading developer and marketer of innovative life-science tools and systems for epigenetics and molecular diagnostics. Diagenode is developing novel products for the infectious disease diagnostic market, but is also providing a complete solution for epigenetics research. Diagenode’s customers include leading epigenetics researchers, academic institutions, molecular diagnostics, pharmaceutical and biotechnology companies. Diagenode’s products provide customers with the best quality and performance and allow scientists to produce consistent, cost-effective and robust results.

[1]Eurosurveillance, Volume 18, Issue 1, 03 January 2013

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: Becton, Dickinson and Company


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

New Gastrointestinal Tract Infections Assays Launch in Europe

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BD | Diagenode
Contact: Jamie Yacco - 
201-847-4796 Jamie_Yacco[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From Becton, Dickinson and Company / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...


Visit  Intrinsic Executive Search Ltd

Visit  MagLar, Inc.


  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today